Neurocrine Biosciences (LTS:0K6R) ROCE %: 18.69% (As of Mar. 2026)


LTS:0K6R Neurocrine Biosciences Inc LTS:0K6R
96 GF Score
Price $168.33
GF Value $185.19
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences ROCE %?

Neurocrine Biosciences LTS:0K6R +0.13% 96 ROCE % is 18.69% as of Mar. 2026. GuruFocus rates LTS:0K6R with a GF Score™ of 96/100 and a GF Value™ of $185.19 (Fairly Valued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Neurocrine Biosciences's annualized ROCE % for the quarter that ended in Mar. 2026 was 18.69%.

Neurocrine Biosciences  (LTS:0K6R) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Neurocrine Biosciences ROCE % Related Terms

Neurocrine Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences ROCE % Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.54 13.62 17.83 21.10 17.93

Neurocrine Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.97 17.90 27.46 24.26 18.69
LTS:0K6R
96GF Score
Neurocrine Biosciences Inc LTS:0K6R
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences ROCE % Calculation

Neurocrine Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=636.5/( ( (3718.7 - 507.7) + (4631.5 - 743.4) )/ 2 )
=636.5/( (3211+3888.1)/ 2 )
=636.5/3549.55
=17.93 %

Neurocrine Biosciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=744/( ( (4631.5 - 743.4) + (4906.2 - 831.7) )/ 2 )
=744/( ( 3888.1 + 4074.5 )/ 2 )
=744/3981.3
=18.69 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 18.69% mean?
Neurocrine Biosciences (LTS:0K6R) has a ROCE % of 18.69% as of Mar. 2026.
Is Neurocrine Biosciences' ROCE % too high?
Neurocrine Biosciences' current ROCE % is 18.69%. The Drug Manufacturers industry median ROCE % is 7.01. Neurocrine Biosciences' value of 18.69% is 166.6% above this industry median. Overall, Neurocrine Biosciences has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' ROCE % compare to VTRS and ELAN?
Neurocrine Biosciences' ROCE % of 18.69% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Neurocrine Biosciences' value of 18.69% is 166.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current ROCE % of 18.69% is 166.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current ROCE % is 18.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Fairly Valued. The stock's GF Value™ is $185.19, compared to a current price of $168.33 — trading 9.1% below its estimated fair value. The current ROCE % is 18.69% and 166.6% above the Drug Manufacturers industry median of 7.01. Neurocrine Biosciences' overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current ROCE % is 18.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of $168.33 is trading 9.1% below its estimated GF Value™ of $185.19. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for LTS:0K6R:

  • ROCE %: 18.69%
  • GF Value™: $185.19 vs. price of $168.33 (9.1% below fair value)
  • GF Score™: 96/100 with 6 warning signs
  • Industry Position: 166.6% above the Drug Manufacturers median

No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
96GF Score

Get the complete analysis for LTS:0K6R

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$168.33
Price
$185.19
GF Value